Key result
Long-term growth hormone therapy in patients with hypochondroplasia yielded a good initial response but was insufficient to achieve an adequate final height.
Why the study?
Does long-term growth hormone therapy improve final height in patients with hypochondroplasia?
Observational (n=6)
Does long-term growth hormone therapy improve final height in patients with hypochondroplasia?
Long-term growth hormone therapy in hypochondroplasia patients showed an initial response but failed to achieve an adequate final height.
Long-term GH may not ensure adequate final height in hypochondroplasia; leaves open need for controlled trials.
Hypochondroplasia is a cause of disproportionate short stature and characterized by minor clinical manifestations. The aim of this study was to evaluate the efficacy of long-term growth hormone (GH) therapy in hypochondroplastic cases with inadequate response to GH stimulation tests. In this study, six patients who had a height standard deviation score of -3.43 before the treatment and a mean age of 7.42 years and who had received GH treatment at a dose of 0.2 mg/kg/week for a mean period of 4.45 years were evaluated. A good response was found in the first year of treatment, but this increase was not found to be sufficient for the patients to achieve an adequate final height.
No takes yet. Share an insight, caveat, or question.
Çetin et al. (2018) conducted an observational in Hypochondroplasia (n=6). Growth hormone (GH) was evaluated on Final height. Long-term growth hormone therapy in patients with hypochondroplasia yielded a good initial response but was insufficient to achieve an adequate final height.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: